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Fleisher, John V. Heymach, Mark G. Kris, Charles M. Rudin, and Lauren Averett Byers
A B S T R A C T
Purpose
Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-
cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of
the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS).
Patients and Methods
A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo
40mg twice daily, days 1 to 7, and oral TMZ 150 to 200mg/m2/day, days 1 to 5, of a 28-day cycle until
disease progression, unacceptable toxicity, or withdrawal of consent. Response was determined by
imaging at weeks 4 and 8, and every 8 weeks thereafter. Improvement in PFS at 4 months was the
primary end point. Secondary objectives included overall response rate (ORR), overall survival (OS),
and safety and tolerability of veliparib with TMZ. Exploratory objectives included PARP-1 and SLFN11
immunohistochemical expression,MGMT promotermethylation, and circulating tumor cell quantification.
Results
No significant difference in 4-month PFSwas noted between TMZ/veliparib (36%) and TMZ/placebo
(27%; P = .19); median OSwas also not improved significantly with TMZ/veliparib (8.2 months; 95%
CI, 6.4 to 12.2 months; v 7.0 months; 95% CI, 5.3 to 9.5 months; P = .50). However, ORR was
significantly higher in patients receiving TMZ/veliparib compared with TMZ/placebo (39% v 14%;
P = .016). Grade 3/4 thrombocytopenia and neutropenia more commonly occurred with TMZ/
veliparib: 50% versus 9% and 31% versus 7%, respectively. Significantly prolonged PFS (5.7 v
3.6 months; P = .009) and OS (12.2 v 7.5 months; P = .014) were observed in patients with SLFN11-
positive tumors treated with TMZ/veliparib.
Conclusion
Four-month PFS and median OS did not differ between the two arms, whereas a significant im-
provement in ORR was observed with TMZ/veliparib. SLFN11 expression was associated with
improved PFS and OS in patients receiving TMZ/veliparib, suggesting a promising biomarker of
PARP-inhibitor sensitivity in SCLC.
J Clin Oncol 36:2386-2394. © 2018 by American Society of Clinical Oncology. Creative Commons
Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-
nc-nd/4.0/
INTRODUCTION
Therapeutic options for patients with relapsed
small-cell lung cancer (SCLC) have remained
unchanged for three decades. The only Food and
Drug Administration–approved agent for recur-
rent or progressive SCLC is topotecan, on the basis
of three phase III trials,1-3 which showed modest
response rates of 24% in patients with platinum-
sensitive disease and 2% to 6% in platinum-
refractory SCLC.3-6 Median time to progres-
sion with topotecan is short, between 13 and 16
weeks,1,3 and there are no approved regimens
after second-line treatment. More effective ther-
apies in SCLC are critically needed.
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SCLC is characterized by aberrant expression of several genes
implicated in DNA damage repair. Proteomic profiling previously
identified poly (ADP-ribose) polymerase (PARP)-1 as a candidate
drug target.7 Frequent epigenetic silencing of the MGMT gene,
which encodes the DNA-repair protein O6 methylguanine-DNA
methyltransferase (MGMT), also has been demonstrated.8-10 As
such, DNA damage response pathways represent attractive targets
in SCLC.11
Temozolomide (TMZ) is an oral alkylating agent that pro-
duces O6-alkyl-guanine lesions on DNA, which are removed by
MGMT. Left unrepaired, TMZ-induced lesions are cytotoxic and
trigger apoptosis.9,10 We previously showed single-agent activity of
TMZ in patients with relapsed SCLC,12 leading to its incorporation
into treatment guidelines for this disease.13 However, the benefit
provided by single-agent TMZ typically is brief, with median
progression-free survival (PFS) of 3.5 months.12
One well-defined mechanism of resistance to TMZ is through
the PARP-dependent base excision repair pathway.14-16 In several
cancer types, the combination of veliparib (formerly ABT-888), an
oral inhibitor of PARP-1 and PARP-2, and TMZ results in greater
tumor growth delay or regression, relative to TMZ alone.17 Fur-
thermore, PARP inhibitors (PARPi) have single-agent activity in
SCLC models and potentiate the effect of cytotoxic agents.7,18,19 On
the basis of this, PARPi trials have been initiated in SCLC.20,21 In this
multi-institutional, double-blind, placebo-controlled, randomized
phase II study (ClinicalTrials.gov identifier: NCT01638546), we
hypothesized that adding veliparib to TMZ may overcome resis-
tance and improve outcomes in patients with relapsed SCLC
and explored candidate predictive biomarkers, including MGMT
promoter methylation.
PATIENTS AND METHODS
This study was reviewed and approved by the institutional review boards
of each center (Appendix Table A1, online only). Written informed con-
sent was provided by all patients. See the Data Supplement for the trial
protocol.
Eligibility Criteria
Patients had SCLC that was sensitive or refractory to platinum-based
chemotherapy (Fig 1). Sensitive disease was defined as progression or
relapse$ 60 days after completion of first-line chemotherapy.1 Refractory
disease was defined as progression during initial therapy or within 60 days
after completing first-line treatment. For the purposes of this study, pa-
tients receiving third-line therapy and those with refractory disease were all
considered refractory. Patients were eligible if they were $ 18 years of age
and had one or two prior chemotherapeutic regimens, Karnofsky per-
formance status $ 70%, measurable disease per Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1,22 and adequate liver, kidney, and
bone marrow function. Those with asymptomatic progression of disease in
the brain were eligible. Patients were excluded if they had chemotherapy or
radiation treatment within 21 days, leptomeningeal involvement, or
a history of seizures.
Treatment
Veliparib and was provided by the Cancer Therapy Evaluation Pro-
gram at the National Cancer Institute. TMZ was obtained commercially.
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Fig 1. CONSORT diagram. A total of 104 patients
were randomly assigned in a 1:1 fashion, stratified by
sensitive disease or refractory disease and center.
Four patients were not treated: three in the temo-
zolomide (TMZ)/placebo arm (one each: withdrawal
of consent, complications of disease, and concomi-
tant therapy prohibitive to initiate study medication),
and one in the TMZ/veliparib arm (complications of
disease). Forty-six and 54 patients were evaluable for
safety in the TMZ/placebo and TMZ/veliparib arms,
respectively. In the TMZ/placebo arm, 44 patients
were evaluable for response because two patients
were removed for toxicity during the first cycle and
before undergoing imaging, indicated by (*). In the
TMZ/veliparib arm, five patients were removed from
the study, indicated by (*), during the first cycle:
registered ineligible (n = 1), clinical progression
of disease (n = 3), and death due to treatment toxicity
(n = 1). As such, 49 patients were evaluable for
response. AE, adverse event; SCLC, small-cell lung
cancer.
jco.org © 2018 by American Society of Clinical Oncology 2387
Veliparib and Temozolomide in Second-Line Treatment of SCLC
Downloaded from ascopubs.org by Washington University Bernard Becker Medical Library on November 12, 2019 from 128.252.011.235
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
After randomization, treatment was started within 7 days. Patients received
oral veliparib or placebo 40 mg twice daily on days 1 to 7 and oral TMZ
200 mg/m2/day on days 1 to 5 of a 28-day cycle, on the basis of a phase II
study of the combination and our prior experience.23,24 See the Data
Supplement for additional details.
Study Evaluation
Patients were assessed every 2 weeks during the first two cycles and
every 4 weeks thereafter. At each visit, a history, physical examination,
toxicity assessment, CBC, and comprehensive metabolic panel were
performed. At cycle 3 and beyond, patients were required to have a CBC on
day 15. Toxicities were graded using National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.0. Tumor assessments
are described in the Data Supplement.
Immunohistochemistry, Promoter Methylation, Mutational
Analysis, and Circulating Tumor Cell Enumeration
Details are included in the Data Supplement.
Statistical Analysis
The primary end point was improvement in PFS at 4 months in
patients receiving TMZ/veliparib compared with TMZ/placebo. Patients
were stratified according to sensitive disease versus refractory disease
and center. In the phase II study of TMZ in SCLC, which enrolled
sensitive and refractory patients in a proportion of 4:1, PFS at 4 months
was 18% for the combined groups.12 On the basis of these findings, the
expected PFS at 4 months in the control group was 15%.With 50 patients
per arm, the study had 85% power to detect an improvement in 4-month
PFS from 15% to 35% (one-sided type I error, 0.15). All randomly
assigned patients were included in the intent-to-treat analysis.
PFS was calculated as the proportion of patients alive and without dis-
ease progression at 4 months after randomization and compared across
the two arms using a x2 test. A patient who discontinued therapy
before 4 months but was alive without documented progression at
4 months was not considered a failure for this end point. See the Data




Between August 2012 and February 2015, 104 patients from
seven centers in the United States were randomly assigned to
receive veliparib or placebo with TMZ (Fig 1). Baseline charac-
teristics were balanced between treatment arms (Table 1). All 104
randomly assigned patients were included in the intent-to-treat
analysis for PFS and overall survival (OS). Those with diagnostic
imaging at least once beyond baseline were evaluated for response
(n = 93). Safety was assessed in patients who initiated one cycle of
study treatment (n = 100; Fig 1).
Efficacy
At the final analysis, no significant difference in 4-month PFS
was demonstrated between TMZ/veliparib (20 of 55; 36%) and
TMZ/placebo (13 of 49; 27%; P = .19). Median PFSwas 3.8 months
and 2.0 months in the TMZ/veliparib and TMZ/placebo arms,
respectively (log-rank P = .39; hazard ratio, 0.84; 95% CI, 0.56 to
1.25; Fig 2A; Appendix Table A2, online only). The median du-
ration of response was 4.61 months (95% CI, 2.86 to 9.9 months)
and 3.68 months (95% CI, 2.76 months to not achieved) in the
TMZ/veliparib (n = 19) and TMZ/placebo (n = 6) arms, re-
spectively (log rank P = .507). At the time of data cutoff, 19 patients
(18%) remained alive (TMZ/veliparib, n = 9; TMZ/placebo, n = 10).
Median OS was similar between TMZ/veliparib and TMZ/placebo:
8.2 months (95% CI, 6.4 to 12.2 months) versus 7.0 months (95%
CI, 5.3 to 9.5 months; P = .50), respectively (Fig 2B; Appendix
Table A2). One- and 2-year survival rates were 35% and 10%
for TMZ/veliparib versus 30% and 11% for TMZ/placebo,
respectively.
In 93 evaluable patients (Appendix Table A2; Figs 3A and 3B;
Appendix Fig A1, online only), a significantly higher objective
response rate (ORR) was observed in patients receiving TMZ/
veliparib (ORR, 39%; 95% CI, 25% to 54%) versus TMZ/placebo
(ORR, 14%; 95% CI, 5% to 27%; P = .016). Two patients who
received veliparib had a complete response, including one with
sensitive disease who continued to receive treatment, with con-
tinued response for over 2 years.
A preplanned subgroup analysis found that responses were
higher with TMZ/veliparib in both platinum-sensitive and
platinum-refractory patients. In sensitive patients, the ORR for
TMZ/veliparib was 41% (9 of 22) versus 11% (2 of 18) for TMZ/
placebo (P = .055); in refractory patients, the ORR for TMZ/
veliparib was 37% (10 of 27) versus 15% (4 of 26) for TMZ/placebo
(P = .22). Furthermore, the improvement in ORR for TMZ/
veliparib compared with TMZ/placebo was similar for second-
and third-line patients. In patients with one previous line of
therapy, the ORR for TMZ/veliparib was 39% (13 of 33) versus
16% (5 of 31) for TMZ/placebo (P = .047), whereas patients with
two prior lines of therapy had an ORR with TMZ/veliparib of 38%
(6 of 16) versus 8% (1 of 13) with TMZ/placebo (P = .21).










Sex: male/female (No.) 50/54 26/23 24/31
Median age, years (range) 62.5 (31-84) 62 (35 -84) 63 (31-80)
ECOG performance status,
No. (%)
0 29 (28) 13 (27) 16 (29)
1 75 (72) 36 (73) 39 (71)
Smoking history*
Current/former, No. (%) 93 (89) 44 (90) 49 (89)
Pack-year history (range) 5-150 8-150 5-135
Never, No. (%) 4 (4) 1 (2) 3 (5)
Previous lines of therapy,
No. (%)
1 70 (67) 34 (69) 36 (65)
2 34 (33) 15 (31) 19 (35)
Cohort designation, No. (%)
Sensitive 43 (41) 19 (39) 24 (44)




10 (2.5-33) 10 (4.5-25) 10.5 (2.5-33)
New brain metastases,
No. (%)‡
22 (21) 10 (20) 12 (22)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
*Not available (n = 7; in the placebo arm [n = 3], in the veliparib arm [n = 4]).
†Patients with refractory disease, as defined by relapse within 60 days of
completing first-line chemotherapy or in need of third-line therapy.
‡Noted at the time of study entry, target or nontarget lesions.
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Treatment Exposure
One hundred of 104 patients enrolled and randomly assigned
received at least one cycle of treatment. Twelve of the 54 treated patients
(22%) in the TMZ/veliparib arm receivedfive ormore cycles of therapy
(median, 3; range, 1 to 21), compared with six of the 46 patients who
were treated (13%) in the TMZ/placebo arm (median, 2; range, 1 to
19). Reasons for discontinuation of study treatment were disease
progression (81%), unacceptable toxicity related or unrelated to
treatment (6%), intercurrent illness/symptomatic deterioration (4%),
withdrawal of consent (3%), more than a 3-week delay in treatment
administration due to thrombocytopenia (2%), and death (1%).
Toxicity
Table 2 lists the most common treatment-related toxicities.
Hematologic toxicities were the most common adverse effects in
both study arms. After the first 24 patients were accrued and
evaluated for at least one cycle, it was noted that 14 incurred the
following adverse events: grade 3/4 neutropenia (TMZ/veliparib,
n = 7; TMZ/placebo, n = 2); grade 3/4 thrombocytopenia (TMZ/
veliparib, n = 10; TMZ/placebo, n = 3); and grade 4 febrile
neutropenia (TMZ/veliparib, n = 1; leading to sepsis and death).
Four of these patients had their second cycle of treatment held and
subsequently were found to have disease progression at week 8
Time (months)
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Fig 2. Kaplan Meier curves for outcomes. (A) Progression-free (PFS) and (B) overall survival (OS) for the 104 patients with sensitive or refractory small-cell lung cancer in





































































Fig 3. Tumor response. The best calculated percentage change in tumor size on the basis of measurable lesions for (A) 49 evaluable patients in the temozolomide (TMZ)/
veliparib arm and (B) 44 evaluable patients in the TMZ/placebo arm. In the TMZ/veliparib arm, five patients were removed from the study during the first cycle and were not
evaluable for response: registered ineligible (n = 1), clinical progression of disease (n = 3), and death due to treatment toxicity (n = 1). In the TMZ/placebo arm, two patients
were removed for toxicity during the first cycle and before undergoing imaging; thus, they were not evaluable for response; one other patient’s tumor measurements were
not available, although the patient developed progression of disease on the basis of the appearance of new nontarget lesions. CR, complete response; ORR, .overall
response rate; PR, partial response.
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(TMZ/veliparib, n = 3; TMZ/placebo, n = 1). Therefore, the protocol
was amended in October 2013 to reduce the starting dose of TMZ to
150 mg/m2/day to avoid myelosuppression and dose delays. At
the lower dose of TMZ, only three patients treated with TMZ/
veliparib and one treated with TMZ/placebo experienced multiple
dosing delays. Prolonged thrombocytopenia led to treatment ter-
mination for an additional two patients, one in each arm.
PARP-1 and SLFN11 Immunohistochemistry as
Biomarkers
Unlike other cancer types, mutations in DNA repair genes
(eg, BRCA1/2) are uncommon and do not predict PARPi response
in SCLC models.25 Schlafen-11 (SLFN11) regulates response to
DNAdamage and replication stress,26 and was recently identified as
a candidate predictive marker of sensitivity to DNA-damaging
chemotherapies27 and PARPi in several cancers, including
SCLC.18,25,28 Therefore, we amended our original planned bio-
marker analysis to investigate whether PARP-1 or SLFN11 ex-
pression levels predicted clinical benefit of TMZ/veliparib.18,25,28,29
Unstained tumor sections from original diagnostic biopsies
were available from 58 patients (56%), of whom 48 and 47 had
adequate tumor content for PARP-1 and SLFN11 analysis, re-
spectively. PARP-1 expression was detected in 87% of tumors
(H-score range, 0 to 219; median, 78). However, there was no
association between PARP-1 expression and clinical outcomes
( Appendix Fig A2, online only).
For SLFN11 biomarker analysis, we used an H-score cutoff
$ 1 to define SLFN11-positive (n = 23) versus SLFN11-negative
tumors (H-score , 1; n =25; Fig 4A). SLFN11-positive tumors
were equally distributed between the treatment arms (TMZ/
veliparib, n = 12; TMZ/placebo, n = 11). Clinical stage at initial
diagnosis, platinum-sensitivity, and smoking history were not
significantly different between the SLFN11-positive and SLFN11-
negative groups.
Patients with SLFN11-positive tumors treated with TMZ/
veliparib had significantly prolonged PFS (5.7 v 3.6 months;
P = .009) and OS (12.2 v 7.5 months; P = .014) from time of
randomization (Fig 4B). In contrast, no differences in PFS or OS
were observed in those patients treated with TMZ/placebo on the
basis of SLFN11 expression (P = .162 and .634, respectively). The
interaction P value was .0092 (by Cox proportional hazards re-
gression model), demonstrating an improved PFS in patients with
SLFN11-positive disease receiving TMZ/veliparib. ORR was not
significantly different on the basis of SLFN11 levels in either study
arm (Appendix Fig A3, online only; TMZ/veliparib, P = .614;
TMZ/placebo, P = .178). Interestingly, there also was a trend
toward improved OS (from initial diagnosis) in patients with
SLFN11-positive tumors (Fig 4C; P = .058) in the overall patient
population. This may be due to SLFN11 also predicting sensitivity
to platinum chemotherapy and topoisomerase inhibitors,25 which
is associated with improved prognosis in patients with SCLC.
MGMT Promoter Methylation as a Biomarker
Analysis of MGMT promoter methylation30-32 was limited by
the availability of adequate tissue, because sufficient DNA was
present in only 32 tumor samples (TMZ/veliparib, n = 17; TMZ/
placebo, n = 15). The MGMT promoter was methylated in 31% of
the tumor samples tested (seven of 32) and was not associated with
response to treatment among all patients treated (P = .657),
or within either treatment arm (TMZ/veliparib, P = .283; TMZ/
placebo, P = .882). MGMT promoter methylation also was not
associated with improved PFS orOS (Appendix Fig A4, online only).
Table 2. Treatment-Emergent Adverse Events Occurring in $ 10% of Patients
Adverse Event









No. % No. % No. % No. %
Hematologic
Anemia 19 41 23 43 1 2 6 11
Leukopenia 8 17 16 30 3 7 13 24
Lymphopenia 5 11 8 15 12 26 11* 20
Neutropenia 0 0 6 11 3 7 17 31
Febrile Neutropenia 0 0 0 0 0 0 2† 4
Thrombocytopenia 15 33 13 24 4 9 27 50‡
Nonhematologic
Alkaline phosphatase increase 2 4 8 15 0 0 0 0
Anorexia 5 11 10 19 0 0 0 0
Constipation 11 24 9 17 0 0 1 2
Dermatologic§ 3 7 6 11 0 0 0 0
Dizziness 1 2 6 11 0 0 0 0
Fatigue 20 43 24 44 2 4 2 4
Nausea 16 35 22 41 0 0 0 0
Vomiting 6 13 9 17 1 2 0 0
*One patient who received eight cycles of temozolomide/veliparib and experienced grade 4 lymphopenia was hospitalized repeatedly secondary to pneumonia in the
setting of a known history of Mycobacterium avium intracellulare and Nocardia infections.
†Grade 3 and 4 febrile neutropenia were noted in two patients in the temozolomide/veliparib arm; one recovered, and one suffered shock with Klebsiella pneumonia
septicemia and died during the study.
‡Although grade 3 and 4 thrombocytopenia was noted in 50%of patients in the temozolomide/veliparib arm, only one suffered a bleeding sequela (hemoptysis) andwas
found to have an endobronchial lesion on bronchoscopy.
§Dermatologic adverse events included dry skin, pruritus, and maculopapular rash.
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Fig 4. SLFN11 immunohistochemistry (IHC) predicts improved survival. (A) Example images of tumors with negative (neg) and positive (pos) SLFN11 by IHC (scale
bar = 100 uM, 4003magnification). (B) Overall survival (OS) and progression-free survival (PFS) from date of randomization was improved in patients with SLFN11-positive
disease in the temozolomide (TMZ)/veliparib treatment arm (PFS overall interaction log-rank P= .046; OS overall interaction log-rank P= .095). (C) OS from time of diagnosis
trends toward increased survival in patients with SLFN11 positive (IHC score$ 1) disease. (D) Swim-plot of months on trial in the TMZ/veliparib treatment arm color coded
by potential biomarker of response (time calculated from start of treatment to date of last follow-up). Blue indicates SLFN11 positive; (*)MGMT promoter methylation.
(E) Summary of biomarker status (SLFN11;MGMTmethylation; ATM, BRCA2, or CHEK2mutation for patients with response data). Gray indicates biomarker assayed and
not detected; white indicates no data. Best response to treatment in each treatment arm. ATM, ATM mutation; BRCA2, BRCA2 mutation; CR, complete response;
Dx, diagnosis; mo, months; NA, not achieved; PD, progression of disease; PR, partial response; SD, stable disease.
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Circulating Tumor Cells
Baseline circulating tumor cells (CTCs) were evaluated on 94
patients at baseline and ranged from 0 to 262 per 7.5mL. In
univariable analysis, elevated baseline CTCs $ 5, which had been
validated in other tumor types,33-35 seemed to be associated with
worse OS: median OS, 5.6 versus 9.7 months; (P, .001; Appendix
Fig A5A, online only). CTCs after one cycle of treatment were
evaluated in 64 patients. A persistently elevated CTC number $ 5
at cycle 2, day 1, also was associated with worse OS in univariable
analysis: median OS, 7.2 versus 8.8 months (P = .012; Appendix
Fig A5B).
Analysis of Mutations in DNA Damage Response Genes
Targeted sequencing was performed on tumors from few
patients (n = 22) at their respective treating institutions and
revealed mutations in the following DNA repair genes previously
implicated in PARPi response in other disease types: ATM (n = 5),
BRCA2 (n = 1), and CHEK2 (n = 1; Table 3).36 Although none of
these seven mutations previously have been described as delete-
rious to gene/protein function, two (CHEK2 p.E76* and ATM
p.G587fs) may confer functional homologous repair deficiency.
Three patients with DNA repair gene mutations (ATM, n = 2;
CHEK2, n = 1) received TMZ/placebo and had a median OS of
10.4 months, compared with 6.2 months for all patients treated
with TMZ/placebo. In the TMZ/veliparib arm, the four patients
with mutations (ATM, n = 3; BRCA2, n = 1) had a median OS of
8.6 months, compared with 8.1 months for others in this cohort
(Fig 4D). Interestingly, two of the four partial responses with
sequencing data observed in the TMZ/veliparib arm had DNA
repair gene mutations (Fig 4E).
DISCUSSION
This randomized phase II study assessed the efficacy of veliparib,
a PARPi, with TMZ compared with TMZ monotherapy in pa-
tients with relapsed SCLC. Although 4-month PFS did not differ
significantly between veliparib- and placebo-treated patients, we
observed significant improvement in ORR with the addition
of veliparib. Furthermore, we demonstrated for the first time in
a clinical trial that SLFN11—a promising biomarker of PARPi
sensitivity—may identify patients who benefit from PARPi
therapy.
In our prior phase II study of single-agent TMZ, 4-month PFS
was 18%,12 which we hoped to improve significantly by adding
veliparib. However, we found no significant difference in 4-month
PFS between patients in the TMZ/veliparib arm (36%) and those in
the TMZ/placebo arm (27%; P = .19). Although median PFS and
OS in patients receiving TMZ/veliparib were improved numerically
by 1.8 months and 1.2 months, respectively, neither reached
statistical significance. However, the substantially higher ORR and
depth of response observed in patients receiving TMZ/veliparib
(ORR, 39%; 95% CI, 25% to 54%) versus TMZ/placebo (ORR,
14%; 95% CI, 5% to 27%; P = .016) was statistically significant and
is encouraging.
Several reasons may account for the high response rates found
with the combination not translating into an improvement in PFS
or OS. These include more frequent myelosuppression, treatment
delays, dose reductions in patients receiving TMZ/veliparib, and
a higher-than-expected number of platinum-resistant patients
enrolled in the trial. Whereas we anticipated that approximately
20% of the study population would have platinum-refractory
disease, in actuality, this highly resistant patient population rep-
resented the majority of study participants (59%), although well
balanced between the two arms. A recent retrospective study
challenged the premise that platinum sensitivity is associated with
outcomes,37 yet data consistently have shown that those with
platinum-resistant disease treated with cytotoxic agents have
worse PFS and OS, which may have affected the observed study
outcomes.38,39
Preclinical data show that the dose levels chosen for the two
agents in combination is important, with recent data suggesting
that optimal synergy may result from near-maximal dosing of
a PARPi, with substantially submaximal dose exposure of
TMZ.23,24,40,41 Here, in contrast, we used a recommended mon-
otherapy treatment dose and schedule of TMZ (per prior SCLC
study24) and a low dose of veliparib (per a phase II breast cancer
study23). This may have compromised the effectiveness of the
combination, especially because veliparib is relatively less po-
tent compared with other PARPi that produce greater PARP-
DNA trapping, a secondary mechanism by which these agents
function.42-44 Furthermore, hematologic toxicities were greater
with TMZ/veliparib versus TMZ/placebo, including grade 3/4
thrombocytopenia, neutropenia, and anemia, which often were
incidental laboratory findings and not clinically significant.
Cytopenias with TMZ/veliparib were often observed early, leading
to treatment delays and, potentially, loss of response. After such
Table 3. Mutations in DNA Genes Among Patients With Available Next-Generation Sequencing
Patient Arm Platform Mutation PFS/OS (mo) Response
MDA-131753 Veliparib CMS400 ATM:c.8174A.G p.D2725G 9.0/16.0 PR
MSK-031 Veliparib IMPACT BRCA2:c5171T.C p.I1724T 6.0/10.8 PR
MDA-144253 Veliparib CMS50 ATM:c.998C.T p.S333F 4.2/4.2 SD
MDA-149438 Veliparib CMS50 ATM:c.1229T.C p.V410A 6.3/6.3 SD
MSK-021 Control IMPACT ATM:c.5738T.C p.V1913A 4.5/9.2 SD
MSK-049 Control IMPACT ATM:c.1760delG p.G587fs 10.4/10.4 SD
MSK-035 Control IMPACT CHEK2:c226G.T p.E76* 1.8/17.3 SD
Abbreviations: CMS50 and CMS400, amplicon-based panel of 50 and 400 cancer-related genes, respectively; IMPACT, Integrated Mutation Profiling of Actionable
Cancer Targets;MDA,MDAnderson Cancer Center; mo,months;MSK,Memorial Sloan Kettering Cancer Center; OS, overall survival; PFS, progression-free survival; PR,
partial response; SD, stable disease.
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toxicities occurred in 14 of the first 24 patients, the protocol was
amended to start at a lower dose of TMZ. After this change, fewer
patients required treatment delays.
In breast, ovarian, and prostate cancers, mutations in BRCA1/2,
ATM, and other homologous repair genes predict PARPi
response.36,45-47 However, in preclinical models of SCLC, neither
mutations in DNA repair genes nor homologous repair deficiency
scores predict PARPi sensitivity.18,25 In this trial, we tested, for the
first time, SLFN11 expression by immunohistochemistry as
a predictive biomarker of clinical response to PARPi therapy on
the basis of preclinical data from SCLC and other cancers.18,25,27-29
In addition to SLFN11, biomarker analysis included PARP-1
expression7,25 and MGMT promoter hypermethylation,12,30-32
although these were not associated with differences in response
or survival.
In contrast, patients with SLFN11-positive tumors (H-score
$ 1) who received TMZ/veliparib had significantly better PFS and
OS than those treated with TMZ/placebo. This finding is consistent
with several recent preclinical studies in SCLC18,25,28,29 and other
cancer types,29 which have shown greater activity of multiple PARPi,
including veliparib in models expressing relatively high levels of
SLFN11. However, our groups recently have also found that SLFN11
decreases in many models after exposure to chemotherapy,18,25,48
suggesting that a repeat biopsy to assess SLFN11 levels at the time
of study entry may be important to optimize its predictive power,
as opposed to using pretreatment samples from diagnosis.
To our knowledge, this is the first demonstration of SFLN11 as
a predictive biomarker in a randomized, double-blind clinical trial.
SLFN11 warrants further investigation in other trials of PARPi
combinations for SCLC. Should this result be substantiated, high
SLFN11 expression could represent a biomarker in select patients
with SCLC for treatment with PARPi.
In conclusion, despite not achieving the primary end point of
an improvement in 4-month PFS, we did observe significantly
higher ORR in patients with relapsed SCLC treated with TMZ/
veliparib, supporting additional studies of this regimen. Hema-
tologic toxicities were noted with the combination of veliparib and
TMZ, most of which did not lead to untoward clinical events
and were less frequent after adjusting the starting dose of TMZ.
Importantly, we demonstrated that high SLFN11 expression,
a promising candidate biomarker of PARPi sensitivity, predicts
longer survival in patients treated with TMZ/veliparib, sub-
stantiating our preclinical findings. Careful patient selection, ap-
plication of SLFN11 as a biomarker, and optimization of the dosing
schedule have the potential to further improve outcomes of the
combination of PARPi and TMZ in SCLC.
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Fig A1. Tumor response in a patient treated with veliparib and temozolomide. A 57-year-old man with small-cell lung cancer metastatic to the brain, pancreatic tail,
juxtaphrenic nerve, and subcutaneous tissue treated with the temozolomide (TMZ)/veliparib arm. (A) Sagittal T1-weighted magnetic resonance imaging scan with contrast
shows a 1-cm metastasis (arrow) in the right frontal lobe at the time of enrollment in the study. (B) Sagittal T1-weighted magnetic resonance imaging scan with contrast
demonstrates complete resolution of the brain lesion (arrow shows previous location) after therapy with TMZ/veliparib. (C) Axial computed tomography scan (CT) with
contrast in narrow windows illustrates a 5-cm juxtaphrenic nodal mass (arrow) at the time that therapy was commenced. (D) Axial CT with contrast after therapy with TMZ/
veliparib shows significant decrease in the lesion (arrow) compatible with response to therapy. (E) Axial abdominal CT with contrast shows a 5-cm heterogeneously
enhancing lesion in the pancreatic tail (arrows). (F) Axial abdominal CT with contrast after therapy with TMZ/veliparib shows interval decrease in the pancreatic lesion to 3.5
cm. (G) Axial CT with contrast in narrow windows shows a 2.5-cm soft tissue implant (arrow) in the subcutaneous fat overlying the left gluteal muscles. Axial CT with
contrast after treatment with the combination of veliparib and TMZ demonstrates a decrease in the size of the lesion (arrow). Importantly, there was significant pain
associated with the lesion, which improved with temozolomide/veliparib therapy. Ao, aorta; C, colon; IVC, inferior vena cava; H, heart; K, kidney; L, liver; S, spleen.
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Fig A2. Poly (ADP-ribose) polymerase (PARP)-1 expression does not predict improved survival. (A) Progression-free survival (PFS) and (B) overall survival (OS) from date
of randomization was not improved in patients whose tumors expressed PARP-1 by immunohistochemistry in the temozolomide (TMZ)/veliparib arm compared with the
TMZ/placebo arm. IHC, immunohistochemistry; mo, months; NA, not achieved.
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Fig A3. SLFN11 expression does not predict improved response to treatment.Waterfall plots of best Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response
(%) in each treatment arm color coded by SLFN-11 immunohistochemistry (IHC) status (positive, negative, or unknown): (A) temozolomide (TMZ)/placebo and (B) TMZ/
veliparib. Boxplot of RECIST 1.1 responses in each treatment arm by SLFN-11 IHC: (C) TMZ/placebo and (D) TMZ/veliparib; trend toward deeper responses among patients
with SLFN11-positive disease receiving veliparib and TMZ combination. CR, complete response; NA, not available; PD, progression of disease; PR, partial response; SD,
stable disease.
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Fig A4. MGMT promoter methylation did not predict improved survival. (A) Progression-free survival (PFS) and (B) overall survival (OS) from the date of randomization in
patients with known MGMT promoter methylation status. mo, months; NA, not achieved; TMZ, temozolomide.
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Fig A5. Low circulating tumor cell (CTC) numbers were associated with improved outcomes. CTCs, 5 in 7.5mLwere associated with improved survival. (A) At baseline
and (B) at the end of cycle 1, CTCs , 5 in 7.5 mL were associated with improved survival. mo, months; OS, overall survival.
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Table A2. Summary of Efficacy Parameters Categorized by Treatment Received
Parameter
Placebo Arm (n = 49)* Veliparib Arm (n = 55)*
No. % No. %
ORR, P = .016 6 14 19 39
CR† 0 0 1 2
PR 6 14 18 37
SD 24 55 22 45
PD 14 32 81 6
PFS at 4 months, P = .39 (%) 27 36
Median PFS, (months), P = .39 2.0 3.8
95% CI 1.6 to 3.7 3.0 to 4.1
Median OS (months), P = .59 7.0 8.2
95% CI 5.3 to 9.5 6.4 to12.2
Cohort designation (%)
Sensitive disease
ORR, P = .055 11 41
Refractory disease
ORR, P = .22 15 37
Previous lines of therapy received (%)
One, P = .047 16 39
Two, P = .21 8 38
Abbreviations: CR, complete response; ORR, overall response rate; OS, overall survival; PD, progression of disease; PFS, progression-free survival; PR, partial response;
SD, stable disease.
*All 49 and 54 patients randomly assigned to the placebo arm and veliparib arm, respectively, were included in the analysis for PFS and OS, whereas those who
underwent diagnostic imaging at least once beyond baseline were evaluable for response (placebo group, n = 44; veliparib group, n = 49). Responses were all confirmed.
†The patient with the confirmed CR continued to receive treatment for . 21 cycles. There was an additional patient with an unconfirmed CR who withdrew consent
after cycle 1.
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